Defining severity in non-cystic fibrosis bronchiectasis

References

• Pasteur MC, Bilton D, Hill AT. British Thoracic Society guideline for non-CF bronchiectasis. Thorax 2011;65(Suppl 1):i1-58
   Google Scholar
• Cole PJ. Inflammation: a two-edged sword--the model of bronchiectasis. Eur J Respir Dis Suppl 1986;147:6-15
   PubMedGoogle Scholar
• Chalmers JD, Hill AT. Mechanisms of immune dysfunction and bacterial persistence in non-cystic fibrosis bronchiectasis. Mol Immunol 2013;55(1):27-34
   PubMed Web of Science ®Google Scholar
• De Soyza A, Brown JS, Loebinger MR. Research priorities in bronchiectasis. Thorax 2013;68(7):695-6
   PubMed Web of Science ®Google Scholar
• Global strategy for the diagnosis, management, and prevention of chronic obstructive pulmonary disease. Executive summary. Revised 2011. Available from: www.goldcopd.org/uploads/users/files/GOLD_Report_2011_Feb21.pdf
   Google Scholar
• Calverley PM, Anderson JA, Bartolome C, et al. for the TORCH investigators. Salmeterol and fluticasone propionate and survival in chronic obstructive pulmonary disease. N Engl J Med 2007;356(8):775-89
   PubMed Web of Science ®Google Scholar
• British Thoracic Society Scottish Intercollegiate Guidelines Network. British Guideline on the Management of Asthma. Updated 2011. Available from: www.brit-thoracic.org.uk/Portals/0/Clinical%20Information/Asthma/Guidelines/sign101%20June%202011.pdf [Last accessed 27 December 2013]
   Google Scholar
• Chalmers JD, Singanayagam A, Akram AR, et al. Severity assessment tools for predicting mortality in hospitalised patients with community acquired pneumonia. Thorax 2010;65(10):878-83
   PubMed Web of Science ®Google Scholar
• Chalmers JD, Singanayagam A, Akram AR, et al. Safety and efficacy of CURB65 guided antibiotic therapy in community-acquired pneumonia. J Antimicrob Chemother 2011;66(2):416-23
   Google Scholar
• Chalmers JD, Akram AR, Hill AT. Increasing outpatient treatment of mild community-acquired pneumonia: systematic review and meta-analysis. Eur Respir J 2011;37(4):858-64
   PubMed Web of Science ®Google Scholar
• Du Bois RM, Weycker D, Albera C, et al. Ascertainment of individual risk of mortality for patients with idiopathic pulmonary fibrosis. Am J Respir Crit Care Med 2011;184(4):459-66
   PubMed Web of Science ®Google Scholar
• Loebinger MR, Wells AU, Hansell DM, et al. Mortality in bronchiectasis: a long-term study assessing the factors influencing survival. Eur Respir J 2009;34(4):843-9
   PubMed Web of Science ®Google Scholar
• Bhalla M, Turcios N, Aponte V, et al. Cystic fibrosis: scoring system with thin-section CT. Radiology 1991;179(3):783-8
   PubMed Web of Science ®Google Scholar
• Reiff DB, Wells AU, Carr DH, et al.T findings in bronchiectasis: limited value in distinguishing between idiopathic and specific types. AJR Am J Roentgenol 1995;165:261-7
   PubMed Web of Science ®Google Scholar
• Onen ZP, Gulbay BE, Sen E, et al. Analysis of the factors related to mortality in patients with bronchiectasis. Respir Med 2007;101:1390-7
   PubMed Web of Science ®Google Scholar
• Chalmers JD, Goeminne P, Aliberti S, et al. Derivation and validation of the bronchiectasis severity index: an international multicentre observational study. Am J Respir Crit Care Med 2013. [Epub ahead of print]
   Google Scholar
• Martinez-Garcia MA, de Gracia J, Vendrell-Relat M, et al. Multidimensional approach to non-cystic fibrosis bronchiectasis: the FACED score. Eur Respir J 2013. [Epub ahead of print]
   Google Scholar
• Martinez-Garcia MA, De la Rosa Carrillo D, et al. Prognostic value of bronchiectasis in patients with moderate-to-severe chronic obstructive pulmonary disease. Am J Respir Crit Care Med 2013;187(8):823-31
   PubMed Web of Science ®Google Scholar
• Goeminne PC, Scheers H, Decraene A, et al. Risk factors for morbidity and death in non-cystic fibrosis bronchiectasis: a retrospective cross-sectional analysis of CT diagnosed bronchiectatic patients. Respir Res 2012;13:21
   PubMed Web of Science ®Google Scholar
• Goeminne PC, Dupont LJ. Mortality in Non-Cystic fibrosis bronchiectasis: data from a large tertiary hospital in Belgium. Am J Respir Crit Care Med 2013;A3513
   Google Scholar
• Seitz AE, Olivier KN, Adjemian J, et al. Trends in bronchiectasis among medicare beneficiaries in the United States, 2000 to 2007. Chest 2012;142:432-9
   PubMed Web of Science ®Google Scholar
• Ringshausen FC, de Roux A, Pletz MW, et al. Bronchiectasis-associated hospitalizations in Germany, 2005-2011L a population-based study of disease burden and trends. PLoS One 2013;8(8):e71109
   PubMed Web of Science ®Google Scholar
• Roberts ME, Lowndes L, Milne DG, Wong CA. Socioeconomic deprivation, readmissions, mortality and acute exacerbations of bronchiectasis. Intern Med J 2012;42(6):e129-36
   PubMed Web of Science ®Google Scholar
• Joish VN, Spilbury-Cantalupo M, Operschall E, et al. Economic burden of non-cystic fibrosis bronchiectasis in the first year after diagnosis from a US health plan perspective. Appl Health Econ Health Policy 2013;11(3):299-304
   PubMedGoogle Scholar
• Martinez-Garcia MA, Soler-Cataluna JJ, Perpina-Tordera M, et al. Factors associated with lung function decline in adult patients with stable non-cystic fibrosis bronchiectasis. Chest 2007;132(5):1565-72
   PubMed Web of Science ®Google Scholar
• Martinez-Garcia MA, Perpina-Tordera M, Roman-Sanchez P, Soler-Cataluna JJ. Quality of life determinants in patients with clinically stable bronchiectasis. Chest 2005;128(2):739-45
   PubMed Web of Science ®Google Scholar
• Aksamit TR, Carretta E, Daley CL, et al. The Bronchiectasis Research Registry: a Collaborative Research Cohort for Non-Cystic Fibrosis Bronchiectasis. Am J Respir Crit Care Med 2012;185(1):A8654
   Google Scholar
• Hurst JR, Vestbo J, Anzueto A, et al. Susceptibility to exacerbation in chronic obstructive pulmonary disease. N Engl J Med 2010;363:1128-38
   PubMed Web of Science ®Google Scholar
• Wilson CB, Jones PW, O’Leary CJ, et al. Validation of the St. Georges Respiratory Questionnaire in bronchiectasis. Am J Respir Crit Care Med 1997;156(2 pt 1):536-41
   PubMed Web of Science ®Google Scholar
• Quittner AL, Cruz I, Marciel KK, et al. Development and cognitive testing of the quality of life questionnaire for bronchiectasis (QOL-B). Am J Respir Crit Care Med 2009;A4310
   Google Scholar
• Schmit KM, Coeytaux RR, Goode AP, et al. Evaluating cough assessment tools: a systematic review. Chest 2013;144(6):1819-26
   Google Scholar
• Murray MP, Turnbull K, MacQuarrie S, et al. Validation of the Leicester Cough Questionnaire in non-cystic fibrosis bronchiectasis. Eur Respir J 2009;34(1):125-31
   PubMed Web of Science ®Google Scholar
• Sheehan RE, Wells AU, Copley SJ, et al. A comparison of serial computed tomography and functional change in bronchiectasis. Eur Respir J 2002;20:581-7
   PubMed Web of Science ®Google Scholar
• Swinson DR, Symmons D, Suresh U, et al. Decreased survival in patients with co-existent rheumatoid arthritis and bronchiectasis. Br J Rheumatol 1997;36:689-91
   PubMedGoogle Scholar
• Pasteur MC, Helliwell SM, Houghton SJ, et al. An investigation into causative factors in patients with bronchiectasis. Am J Respir Crit Care Med 2000;162(4 pt 1):1277-84
   PubMed Web of Science ®Google Scholar
• Chalmers JD, Smith MP, McHugh B, et al. Short and long term antibiotic therapy reduces airway and systemic inflammation in non-CF bronchiectasis. Am J Respir Crit Care Med 2012;186(7):657-65
   PubMed Web of Science ®Google Scholar
• Roberts H, Wells A, Milne D. Airflow obstruction in bronchiectasis: correlation between computed tomography features and pulmonary function tests. Thorax 2000;55(3):198-204
   PubMed Web of Science ®Google Scholar
• Brody AS, Klein JS, Molina PL, et al. High-resolution computed tomography in young patients with cystic fibrosis: distribution of abnormalities and correlation with pulmonary function tests. J Pediatr 2004;145:32-8
   PubMed Web of Science ®Google Scholar
• Robinson TE, Leung AN, Northway WH, et al. Spirometer-triggered high-resolution computed tomography and pulmonary function measurements during an acute exacerbation in patients with cystic fibrosis. J Pediatr 2001;138:553-9
   Google Scholar
• Agarwal R, Khan A, Gupta D, et al. An Alternate Method of Classifying Allergic Bronchopulmonary Aspergillosis Based on High-Attenuation Mucus. PLoS ONE 2010;5:e15346
   PubMed Web of Science ®Google Scholar
• Devaraj A, Well AU, Meister MG, et al. Pulmonary hypertension in patients with bronchiectasis: prognostic significance of CT signs. AJR Am J Roentgenol 2011;196(6):1300-4
   Google Scholar
• Li Z, Kosorok MR, Farrell PM, et al. Longditudinal development of mucoid Pseudomonas aeruginosa infection and lung disease progression in children with cystic fibrosis. JAMA 2005;293(5):581-8
   PubMed Web of Science ®Google Scholar
• Ratjen F, Munck A, Kho P, Angyalosi G. Treatment of early Pseudomonas aeruginosa infection in patients with cystic fibrosis: the ELITE trial. Thorax 2010;65:286-91
   PubMed Web of Science ®Google Scholar
• Doring G, Conway SP, Heijerman HGM, et al. Antibiotic therapy against Pseudomonas aeruginosa in cystic fibrosis: a European consensus. Eur Respir J 2000;16:749-67
   PubMed Web of Science ®Google Scholar
• Davies G, Wells AU, Doffman S, et al. The effect of Pseudomonas aeruginosa on pulmonary function in patients with bronchiectasis. Eur Respir J 2006;28(5):974-9
   PubMed Web of Science ®Google Scholar
• Evans SA, Turner SM, Bosch BJ, et al. Lung function in bronchiectasis: the influence of Pseudomonas aeruginosa. Eur Respir J 1996;9(8):1601-4
   PubMed Web of Science ®Google Scholar
• Bahous J, Cartier A, Pineau L, et al. Pulmonary function tests and airway responsiveness to methacholine in chronic bronchiectasis of the adult. Bull Eur Physiopathol Respir 1984;20(3):75-80
   Google Scholar
• Murray MP, Turnbull K, Macquarrie S, Hill AT. Assessing response to treatment of exacerbations of bronchiectasis in adults. Eur Respir J 2009;33(2):312-18
   PubMed Web of Science ®Google Scholar
• Ramsey BW, Davies J, McElvaney NG, et al. A CFTR potentiator in patients with cystic fibrosis and the G551D mutation. N Engl J Med 2011;365(18):1663-72
   PubMed Web of Science ®Google Scholar
• Eisen DP. Mannose-binding lectin deficiency and respiratory tract infection. J Innate Immun 2010;2(2):114-22
   PubMed Web of Science ®Google Scholar
• Chalmers JD, Fleming GB, Hill AT, Kilpatrick DC. Impact of mannose binding lectin (MBL) insufficiency on the course of cystic fibrosis: a review and meta-analysis. Glycobiology 2011;21(3):271-82
   Google Scholar
• Chalmers JD, McHugh BJ, Doherty CJ, et al. Mannose binding lectin deficiency and disease severity in non-CF bronchiectasis: a prospective study. Lancet Respiratory Medicine 2013;1(3):175-274
   PubMed Web of Science ®Google Scholar
• Hodge S, Hodge G, Jersmann H, et al. Azithromycin improves macrophage phagocytic function and expression of mannose receptor in chronic obstructive pulmonary disease. Am J Respir Crit Care Med 2008;178(2):139-48
   PubMed Web of Science ®Google Scholar
• Kilpatrick DC, Chalmers JD, MacDonald SL, et al. Stable bronchiectasis is associated with low serum L-ficolin concentrations. Clin Respir J 2009;3(1):29-33
   Google Scholar
• Kilpatrick DC, Chalmers JD. Human L-ficolin (ficolin-2) and its clinical significance. J Biomed Biotechnol 2012;2012:138797
   Google Scholar
• Chalmers JD, Kilpatrick DC, McHugh B, et al. Single nucleotide polymorphisms in the ficolin-2 gene predispose to Pseudomonas aeruginosa infection and disease severity in non-cystic fibrosis bronchiectasis. Thorax 2011;66(4):A1-2
   Google Scholar
• Hsieh MH, Chou PC, Chou CL, et al. Matrix metalloproteinase-1 polymorphism (-1607G) and disease severity in non-cystic fibrosis bronchiectasis in Taiwan. PLoS ONE 2013;8(6):e66265
   PubMed Web of Science ®Google Scholar
• Bienvenu T, Sermet-Gaudelus I, Burgel PR, et al. Cystic fibrosis transmembrane conductance regulator channel dysfunction in non-cystic fibrosis bronchiectasis. Am J Respir Crit Care Med 2010;181:1078-84
   PubMed Web of Science ®Google Scholar
• Boyton RJ, Smith J, Ward R, et al. HLA-C and killer cell. immunoglobulin-like receptor genes in idiopathic bronchiectasis. Am J Respir Crit Care Med 2006;173:327-33
   Google Scholar
• Boyton RJ, Smith J, Jones M, et al. Human leukocyte antigen class II association in idiopathic bronchiectasis, a disease of chronic lung infection, implicates a role for adaptive immunity. Clin Exp Immunol 2008;152(1):95-101
   Google Scholar
• Fuschillo S, De Felice A, Balzano G. Mucosal inflammation in idiopathic bronchiectasis: cellular and molecular mechanisms. Eur Respir J 2008;31:396-406
   PubMed Web of Science ®Google Scholar
• Watt AP, Brown V, Courtney J, et al. Neutrophil apoptosis, proinflammatory mediators and cell counts in bronchiectasis. Thorax 2004;59(3):231-6
   Google Scholar
• Angrill J, Agusti C, De Celis R, et al. Bronchial inflammation and colonization in patients with clinically stable bronchiectasis. Am J Respir Crit Care Med 2001;164(9):1628-32
   Google Scholar
• Hill AT, Campbell EJ, Hill SL, et al. Association between airway bacterial load and markers of airway inflammation in patients with stable chronic bronchitis. Am J Med 2000;109(4):288-95
   PubMed Web of Science ®Google Scholar
• Sly PD, Gangell CL, Chen L, et al. Risk factors for bronchiectasis in children with cystic fibrosis. N Engl J Med 2013;368(21):1963-70
   PubMed Web of Science ®Google Scholar
• Sagel SD, Wagner BD, Anthony MM, et al. Sputum biomarkers of inflammation and lung function decline in children with cystic fibrosis. Am J Respir Crit Care Med 2012;186(9):857-65
   PubMed Web of Science ®Google Scholar
• Murray MP, Pentland JL, Turnbull K, et al. Sputum colour: a useful clinical tool in non-cystic fibrosis bronchiectasis. Eur Respir J 2009;34(2):361-4
   PubMed Web of Science ®Google Scholar
• Goeminne PC, Vandooren J, Moelants EA, et al. The sputum colour chart as a predictor of lung inflammation, proteolysis and damage in non-cystic fibrosis bronchiectasis: a case-control analysis. Respirology 2013. [Epub ahead of print]
   Google Scholar
• Shoemark A, Debaraj A, Meister M, et al. Elevated peripheral airway nitric oxide in bronchiectasis reflects disease severity. Respir Med 2011;105(6):885-91
   PubMed Web of Science ®Google Scholar
• Zheng L, Tipoe G, Lam WK. Upregulation of circulation adhesion molecules in bronchiectasis. Eur Respir J 2000;16(4):691-6
   Google Scholar
• Wilson CB, Jones PW, O’Leary CJ, et al. Systemic markers of inflammation in stable bronchiectasis. Eur Respir J 1998;12(4):820-4
   Google Scholar
• Lee AL, Button BM, Denehy L, et al. Proximal and distal gastro-oseophageal reflux in COPD and bronchiectasis. Respirology 2013. [Epub ahead of print]
   Google Scholar
• Mandal P, Morice A, Chalmers JD, Hill AT. Symptoms of airway reflux predict exacerbations and quality of life in bronchiectasis. Respir Med 2013;107(7):1008-13
   PubMed Web of Science ®Google Scholar
• Bronchiectasis severity index. Available from: www.bronchiectasisseverity.com
   Google Scholar
• Wong C, Jayaram L, Karalus N, et al. Azithromycin for prevention of exacerbations in non-cystic fibrosis bronchiectasis (EMBRACE): a randomised, double-blind, placebo-controlled trial. Lancet 2012;380(9842):660-7
   PubMed Web of Science ®Google Scholar
• Altenburg J, de Graff CS, Stienstra Y, et al. Effect of azithromycin maintenance treatment on infectious exacerbations among patients with non-cystic fibrosis bronchiectasis: the BAT randomized controlled trial. JAMA 2013;309(12):1251-9
   PubMed Web of Science ®Google Scholar
• Serisier DJ, Martin ML, McGuckin MA, et al. Effect of long-term, low-dose erythromycin on pulmonary exacerbations among patients with non-cystic fibrosis bronchiectasis: the BLESS randomized controlled trial. JAMA 2013;309(12):1260-7
   PubMed Web of Science ®Google Scholar
• Albert RK, et al. Azithromycin for prevention of exacerbations of COPD. N Engl J Med 2011;365(8):689-98
   PubMed Web of Science ®Google Scholar
• Ray WA, Murray KT, Hall K, et al. Azithromycin and the risk of cardiovascular death. N Engl J Med 2012;366(20):1881-90
   PubMed Web of Science ®Google Scholar
• Schembri S, Williamson PA, Short PM, et al. Cardiovascular events following Clarithromycin use in lower respiratory tract infections: analysis of two prospective cohort studies. BMJ 2013;346:f1235
   PubMed Web of Science ®Google Scholar
• Murray MP, Govan JRW, Docherty CJ, et al. A randomised controlled trial of nebulised gentamicin in non-cystic fibrosis bronchiectasis. Am J Respir Crit Care Med 2011;183(4):491-9
   PubMed Web of Science ®Google Scholar
• Serisier DJ, Bilton D, De Soyza A, et al. Inhaled, dual release liposomal ciprofloxacin in non-cystic bronchiectasis (ORBIT-2), a randomised double-blind placebo controlled trial. Thorax 2013;68(9):812-17
   PubMed Web of Science ®Google Scholar
• Wilson R, Welte T, Polverino E, et al. Ciprofloxacin dry powder for inhalation in non-cystic fibrosis bronchiectasis: a phase II randomised study. Eur Respir J 2013;41(5):1107-15
   PubMed Web of Science ®Google Scholar
• McShane PJ, Naureckas ET, Tino G, Strek ME. Concise clinical review: non-cystic fibrosis bronchiectasis. Am J Respir Crit Care Med 2013;188(6):647-56
   PubMed Web of Science ®Google Scholar
• Chalmers JD, McHugh BJ, Doherty CJ, et al. Vitamin-D deficiency is associated with chronic bacterial colonisation and disease severity in non-CF bronchiectasis. Thorax 2012;68(1):39-47
   PubMedGoogle Scholar
• Mandal P, Sidhu MK, Donaldsn LS, et al. Eight-weekly intravenous antibiotics is beneficial in severe bronchiectasis. QJM 2013;106(1):27-33
   PubMed Web of Science ®Google Scholar
• Tunney MM, Einarsson GG, Wei L, et al. Lung microbiota and bacterial abundance in patients with bronchiectasis when clinically stable and during exacerbation. Am J Respir Crit Care Med 2013;187(10):118-26
   Google Scholar